Highlights

September 23, 2020 08:00 AM Eastern Daylight Time   ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that it will be participating in Precision Medicine’s webinar on utilizing liquid biopsy to

Seoul Office Will Be Opening to Develop Immunomic Therapeutics Investigational Cell Therapy for Brain Cancer September 10, 2020 08:00 AM Eastern Daylight Time SEOUL--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held

ITI was chosen as one of DC Inno’s on Fire Winners for 2020 alongside Emergent Biosolutions, Novavax and Viela Bio. Check it out… https://www.americaninno.com/dc/50-on-fire/meet-dc-innos-2020-Inno-on-fire DC Inno is your source for

- ITI-1000 targets CMV with Immunomic Therapeutics’ immunotherapy UNITE™ platform - ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. announced today that it has assumed sponsorship of the Investigational New Drug (IND)

ITI's Michael Connolly, Manager of Process Development, presents a poster titled, "Functional evaluation of isoforms present in pDNA vaccines" at Aldevron's corporate offices located in Fargo, North Dakota A detailed abstract

 Immunomic Therapeutics, Inc. Founder and CEO Bill Hearl Joins Rich Bendis for BioTalk Click to hear the interview: Bill Hearl Q&A Dr. Bill Hearl is the Founder and Chief Executive Officer

Our very own Dr. Heiland has been featured on BioBuzz.  Click below to read the full Q&A Interview, as Dr. Heiland discusses our technology platform name change to UNITE and

Please read the article authored by ITI titled, “The Use and Misuse of Cancer Life Expectancy Statistics” which explores how GBM patients adjust and deal with dire life expectancy statistics.

      Congratulations to Immunomic and Astellas for winning the Best Therapeutic Vaccine award for ASP0892 (Peanut Vaccine)!

Scientific American’s Custom Media division hosted a unique salon-style event in collaboration with Immunomic Therapeutics on Monday, February 12th in the heart of Manhattan’s Times Square. The forum, Hot Topics in Biotech:

Read how Astellas is working to address a high unmet medical need with first-of-its-kind allergy vaccine development through an innovative partnership. The following article was authored by Astellas and published on

Scientific American custom media and Immunomic Therapeutics released an article titled, “The Fight Against Cancer is Increasingly Personal,” by reclassifying tumors, scientists are finding a path to genuine cancer cures.